Induction of B cell tumor dormancy by anti-idiotypic antibodies
- 31 October 1993
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 5 (5), 740-744
- https://doi.org/10.1016/0952-7915(93)90130-k
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Growth Inhibition of Human Lymphoma Cell Lines by the Marine Products, Dolastatins 10 and 15JNCI Journal of the National Cancer Institute, 1993
- Elimination of self-reactive B lymphocytes proceeds in two stages: Arrested development and cell deathCell, 1993
- Cladribine (2-chlorodeoxyadenosine)The Lancet, 1992
- Synergy between TGF-β and Anti-IgM in Growth Inhibition of CD5+ B-Cell LymphomasaAnnals of the New York Academy of Sciences, 1992
- Immunotherapy of B lymphoma by anti-idiotype antibodies: Characterization of variant tumour cells appearing a long time after the initial tumour inoculationCancer Immunology, Immunotherapy, 1991
- Prospects for the Treatment of B Cell Tumors Using Idiotypic VaccinationInternational Reviews of Immunology, 1989
- Development of a New Therapeutic Approach to B Cell Malignancy. The Induction of Immunity by the Host Against Cell Surface Receptor on the TumorInternational Reviews of Immunology, 1989
- Fos and jun: The AP-1 connectionCell, 1988
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- Spontaneous murine B-cell leukaemiaNature, 1978